Please contact our sales team for your Consulting and Customization queries/concerns at [email protected].
Bimatoprost (CAS 155206-00-1), also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.
The global Latisse (Bimatoprost) market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
Global Latisse (Bimatoprost) (CAS 155206-00-1) key players include Chirogate International, Cayman Pharma, Zhejiang Ausun, Everlight Chemical, and Lianmin Biochemical etc. Global top three players hold a share about 40%. North America is the largest market, with a share about 90%.
Report Includes:
This report presents an overview of global market for Latisse (Bimatoprost), sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Latisse (Bimatoprost), also provides the sales of main regions and countries. Highlights of the upcoming market potential for Latisse (Bimatoprost), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Latisse (Bimatoprost) sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2023. Identification of the major stakeholders in the global Latisse (Bimatoprost) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by purity and by application, sales, revenue, and price, from 2018 to 2029. Evaluation and forecast the market size for Latisse (Bimatoprost) sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Cayman Pharma, Tecoland Corporation, TCS Group, Changzhou BOHIV, Zhejiang Ausun, Ansion Pharma, Lianmin Biochemical, Chirogate International and Everlight Chemical, etc.
By Company
- Cayman Pharma
- Tecoland Corporation
- TCS Group
- Changzhou BOHIV
- Zhejiang Ausun
- Ansion Pharma
- Lianmin Biochemical
- Chirogate International
- Everlight Chemical
- GENTEC
Segment by Purity
- Below 99.5%
- Other
Segment by Application
- Patented Product
- General Products
Segment By Region
- US & Canada
- - U.S.
- - Canada
- China
- Asia (excluding China)
- - Japan
- - South Korea
- - China Taiwan
-- Southeast Asia
- - India
- Europe
- - Germany
- - France
- - U.K.
- - Italy
- - Russia
- Middle East, Africa, Latin America
- - Brazil
- - Mexico
- - Turkey
- - Israel
- - GCC Countries
Chapter Outline
Chapter 1: Introduces the Report Scope of the report, executive summary of different market segments (by purity and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Latisse (Bimatoprost) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Latisse (Bimatoprost) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by purity, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: US & Canada (US & Canada) by purity, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by purity, by application and by country, sales and revenue for each segment.
Chapter 8: China by purity, by application sales and revenue for each segment.
Chapter 9: Asia (excluding China) by purity, by application and By Region, sales and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by purity, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Latisse (Bimatoprost) sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
Table of Contents
1 Study Coverage
1.1 Latisse (Bimatoprost) Product Introduction
1.2 Market by Purity
1.2.1 Global Latisse (Bimatoprost) Market Size Growth Rate by Purity, 2018 VS 2022 VS 2029
1.2.2 Below 99.5%
1.2.3 Other
1.3 Market by Application
1.3.1 Global Latisse (Bimatoprost) Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Patented Product
1.3.3 General Products
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Latisse (Bimatoprost) Sales Estimates and Forecasts 2018-2029
2.2 Global Latisse (Bimatoprost) Revenue by Region
2.2.1 Global Latisse (Bimatoprost) Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Latisse (Bimatoprost) Revenue by Region (2018-2023)
2.2.3 Global Latisse (Bimatoprost) Revenue by Region (2024-2029)
2.2.4 Global Latisse (Bimatoprost) Revenue Market Share by Region (2018-2029)
2.3 Global Latisse (Bimatoprost) Sales Estimates and Forecasts 2018-2029
2.4 Global Latisse (Bimatoprost) Sales by Region
2.4.1 Global Latisse (Bimatoprost) Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Latisse (Bimatoprost) Sales by Region (2018-2023)
2.4.3 Global Latisse (Bimatoprost) Sales by Region (2024-2029)
2.4.4 Global Latisse (Bimatoprost) Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Latisse (Bimatoprost) Sales by Manufacturers
3.1.1 Global Latisse (Bimatoprost) Sales by Manufacturers (2018-2023)
3.1.2 Global Latisse (Bimatoprost) Sales Market Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Latisse (Bimatoprost) in 2022
3.2 Global Latisse (Bimatoprost) Revenue by Manufacturers
3.2.1 Global Latisse (Bimatoprost) Revenue by Manufacturers (2018-2023)
3.2.2 Global Latisse (Bimatoprost) Revenue Market Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Latisse (Bimatoprost) Revenue in 2022
3.3 Global Key Players of Latisse (Bimatoprost), Industry Ranking, 2021 VS 2022 VS 2023
3.4 Global Latisse (Bimatoprost) Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Latisse (Bimatoprost) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Latisse (Bimatoprost), Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Latisse (Bimatoprost), Product Offered and Application
3.8 Global Key Manufacturers of Latisse (Bimatoprost), Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Purity
4.1 Global Latisse (Bimatoprost) Sales by Purity
4.1.1 Global Latisse (Bimatoprost) Historical Sales by Purity (2018-2023)
4.1.2 Global Latisse (Bimatoprost) Forecasted Sales by Purity (2024-2029)
4.1.3 Global Latisse (Bimatoprost) Sales Market Share by Purity (2018-2029)
4.2 Global Latisse (Bimatoprost) Revenue by Purity
4.2.1 Global Latisse (Bimatoprost) Historical Revenue by Purity (2018-2023)
4.2.2 Global Latisse (Bimatoprost) Forecasted Revenue by Purity (2024-2029)
4.2.3 Global Latisse (Bimatoprost) Revenue Market Share by Purity (2018-2029)
4.3 Global Latisse (Bimatoprost) Price by Purity
4.3.1 Global Latisse (Bimatoprost) Price by Purity (2018-2023)
4.3.2 Global Latisse (Bimatoprost) Price Forecast by Purity (2024-2029)
5 Market Size by Application
5.1 Global Latisse (Bimatoprost) Sales by Application
5.1.1 Global Latisse (Bimatoprost) Historical Sales by Application (2018-2023)
5.1.2 Global Latisse (Bimatoprost) Forecasted Sales by Application (2024-2029)
5.1.3 Global Latisse (Bimatoprost) Sales Market Share by Application (2018-2029)
5.2 Global Latisse (Bimatoprost) Revenue by Application
5.2.1 Global Latisse (Bimatoprost) Historical Revenue by Application (2018-2023)
5.2.2 Global Latisse (Bimatoprost) Forecasted Revenue by Application (2024-2029)
5.2.3 Global Latisse (Bimatoprost) Revenue Market Share by Application (2018-2029)
5.3 Global Latisse (Bimatoprost) Price by Application
5.3.1 Global Latisse (Bimatoprost) Price by Application (2018-2023)
5.3.2 Global Latisse (Bimatoprost) Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Latisse (Bimatoprost) Market Size by Purity
6.1.1 US & Canada Latisse (Bimatoprost) Sales by Purity (2018-2029)
6.1.2 US & Canada Latisse (Bimatoprost) Revenue by Purity (2018-2029)
6.2 US & Canada Latisse (Bimatoprost) Market Size by Application
6.2.1 US & Canada Latisse (Bimatoprost) Sales by Application (2018-2029)
6.2.2 US & Canada Latisse (Bimatoprost) Revenue by Application (2018-2029)
6.3 US & Canada Latisse (Bimatoprost) Market Size by Country
6.3.1 US & Canada Latisse (Bimatoprost) Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Latisse (Bimatoprost) Sales by Country (2018-2029)
6.3.3 US & Canada Latisse (Bimatoprost) Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Latisse (Bimatoprost) Market Size by Purity
7.1.1 Europe Latisse (Bimatoprost) Sales by Purity (2018-2029)
7.1.2 Europe Latisse (Bimatoprost) Revenue by Purity (2018-2029)
7.2 Europe Latisse (Bimatoprost) Market Size by Application
7.2.1 Europe Latisse (Bimatoprost) Sales by Application (2018-2029)
7.2.2 Europe Latisse (Bimatoprost) Revenue by Application (2018-2029)
7.3 Europe Latisse (Bimatoprost) Market Size by Country
7.3.1 Europe Latisse (Bimatoprost) Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Latisse (Bimatoprost) Sales by Country (2018-2029)
7.3.3 Europe Latisse (Bimatoprost) Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Latisse (Bimatoprost) Market Size
8.1.1 China Latisse (Bimatoprost) Sales (2018-2029)
8.1.2 China Latisse (Bimatoprost) Revenue (2018-2029)
8.2 China Latisse (Bimatoprost) Market Size by Application
8.2.1 China Latisse (Bimatoprost) Sales by Application (2018-2029)
8.2.2 China Latisse (Bimatoprost) Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Latisse (Bimatoprost) Market Size by Purity
9.1.1 Asia Latisse (Bimatoprost) Sales by Purity (2018-2029)
9.1.2 Asia Latisse (Bimatoprost) Revenue by Purity (2018-2029)
9.2 Asia Latisse (Bimatoprost) Market Size by Application
9.2.1 Asia Latisse (Bimatoprost) Sales by Application (2018-2029)
9.2.2 Asia Latisse (Bimatoprost) Revenue by Application (2018-2029)
9.3 Asia Latisse (Bimatoprost) Sales by Region
9.3.1 Asia Latisse (Bimatoprost) Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Latisse (Bimatoprost) Revenue by Region (2018-2029)
9.3.3 Asia Latisse (Bimatoprost) Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Latisse (Bimatoprost) Market Size by Purity
10.1.1 Middle East, Africa and Latin America Latisse (Bimatoprost) Sales by Purity (2018-2029)
10.1.2 Middle East, Africa and Latin America Latisse (Bimatoprost) Revenue by Purity (2018-2029)
10.2 Middle East, Africa and Latin America Latisse (Bimatoprost) Market Size by Application
10.2.1 Middle East, Africa and Latin America Latisse (Bimatoprost) Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Latisse (Bimatoprost) Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Latisse (Bimatoprost) Sales by Country
10.3.1 Middle East, Africa and Latin America Latisse (Bimatoprost) Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Latisse (Bimatoprost) Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Latisse (Bimatoprost) Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Cayman Pharma
11.1.1 Cayman Pharma Company Information
11.1.2 Cayman Pharma Overview
11.1.3 Cayman Pharma Latisse (Bimatoprost) Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 Cayman Pharma Latisse (Bimatoprost) Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Cayman Pharma Recent Developments
11.2 Tecoland Corporation
11.2.1 Tecoland Corporation Company Information
11.2.2 Tecoland Corporation Overview
11.2.3 Tecoland Corporation Latisse (Bimatoprost) Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 Tecoland Corporation Latisse (Bimatoprost) Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Tecoland Corporation Recent Developments
11.3 TCS Group
11.3.1 TCS Group Company Information
11.3.2 TCS Group Overview
11.3.3 TCS Group Latisse (Bimatoprost) Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 TCS Group Latisse (Bimatoprost) Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 TCS Group Recent Developments
11.4 Changzhou BOHIV
11.4.1 Changzhou BOHIV Company Information
11.4.2 Changzhou BOHIV Overview
11.4.3 Changzhou BOHIV Latisse (Bimatoprost) Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 Changzhou BOHIV Latisse (Bimatoprost) Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Changzhou BOHIV Recent Developments
11.5 Zhejiang Ausun
11.5.1 Zhejiang Ausun Company Information
11.5.2 Zhejiang Ausun Overview
11.5.3 Zhejiang Ausun Latisse (Bimatoprost) Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 Zhejiang Ausun Latisse (Bimatoprost) Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Zhejiang Ausun Recent Developments
11.6 Ansion Pharma
11.6.1 Ansion Pharma Company Information
11.6.2 Ansion Pharma Overview
11.6.3 Ansion Pharma Latisse (Bimatoprost) Sales, Price, Revenue and Gross Margin (2018-2023)
11.6.4 Ansion Pharma Latisse (Bimatoprost) Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Ansion Pharma Recent Developments
11.7 Lianmin Biochemical
11.7.1 Lianmin Biochemical Company Information
11.7.2 Lianmin Biochemical Overview
11.7.3 Lianmin Biochemical Latisse (Bimatoprost) Sales, Price, Revenue and Gross Margin (2018-2023)
11.7.4 Lianmin Biochemical Latisse (Bimatoprost) Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Lianmin Biochemical Recent Developments
11.8 Chirogate International
11.8.1 Chirogate International Company Information
11.8.2 Chirogate International Overview
11.8.3 Chirogate International Latisse (Bimatoprost) Sales, Price, Revenue and Gross Margin (2018-2023)
11.8.4 Chirogate International Latisse (Bimatoprost) Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Chirogate International Recent Developments
11.9 Everlight Chemical
11.9.1 Everlight Chemical Company Information
11.9.2 Everlight Chemical Overview
11.9.3 Everlight Chemical Latisse (Bimatoprost) Sales, Price, Revenue and Gross Margin (2018-2023)
11.9.4 Everlight Chemical Latisse (Bimatoprost) Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Everlight Chemical Recent Developments
11.10 GENTEC
11.10.1 GENTEC Company Information
11.10.2 GENTEC Overview
11.10.3 GENTEC Latisse (Bimatoprost) Sales, Price, Revenue and Gross Margin (2018-2023)
11.10.4 GENTEC Latisse (Bimatoprost) Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 GENTEC Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Latisse (Bimatoprost) Industry Chain Analysis
12.2 Latisse (Bimatoprost) Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Latisse (Bimatoprost) Production Mode & Process
12.4 Latisse (Bimatoprost) Sales and Marketing
12.4.1 Latisse (Bimatoprost) Sales Channels
12.4.2 Latisse (Bimatoprost) Distributors
12.5 Latisse (Bimatoprost) Customers
13 Market Dynamics
13.1 Latisse (Bimatoprost) Industry Trends
13.2 Latisse (Bimatoprost) Market Drivers
13.3 Latisse (Bimatoprost) Market Challenges
13.4 Latisse (Bimatoprost) Market Restraints
14 Key Findings in The Global Latisse (Bimatoprost) Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Latisse (Bimatoprost) Market Size Growth Rate by Purity, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Below 99.5%
Table 3. Major Manufacturers of Other
Table 4. Global Latisse (Bimatoprost) Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global Latisse (Bimatoprost) Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Latisse (Bimatoprost) Revenue by Region (2018-2023) & (US$ Million)
Table 7. Global Latisse (Bimatoprost) Revenue by Region (2024-2029) & (US$ Million)
Table 8. Global Latisse (Bimatoprost) Revenue Market Share by Region (2018-2023)
Table 9. Global Latisse (Bimatoprost) Revenue Market Share by Region (2024-2029)
Table 10. Global Latisse (Bimatoprost) Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 11. Global Latisse (Bimatoprost) Sales by Region (2018-2023) & (g)
Table 12. Global Latisse (Bimatoprost) Sales by Region (2024-2029) & (g)
Table 13. Global Latisse (Bimatoprost) Sales Market Share by Region (2018-2023)
Table 14. Global Latisse (Bimatoprost) Sales Market Share by Region (2024-2029)
Table 15. Global Latisse (Bimatoprost) Sales by Manufacturers (2018-2023) & (g)
Table 16. Global Latisse (Bimatoprost) Sales Share by Manufacturers (2018-2023)
Table 17. Global Latisse (Bimatoprost) Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 18. Global Latisse (Bimatoprost) Revenue Share by Manufacturers (2018-2023)
Table 19. Global Key Players of Latisse (Bimatoprost), Industry Ranking, 2021 VS 2022 VS 2023
Table 20. Latisse (Bimatoprost) Price by Manufacturers 2018-2023 (US$/g)
Table 21. Global Latisse (Bimatoprost) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Latisse (Bimatoprost) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Latisse (Bimatoprost) as of 2022)
Table 23. Global Key Manufacturers of Latisse (Bimatoprost), Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Latisse (Bimatoprost), Product Offered and Application
Table 25. Global Key Manufacturers of Latisse (Bimatoprost), Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Latisse (Bimatoprost) Sales by Purity (2018-2023) & (g)
Table 28. Global Latisse (Bimatoprost) Sales by Purity (2024-2029) & (g)
Table 29. Global Latisse (Bimatoprost) Sales Share by Purity (2018-2023)
Table 30. Global Latisse (Bimatoprost) Sales Share by Purity (2024-2029)
Table 31. Global Latisse (Bimatoprost) Revenue by Purity (2018-2023) & (US$ Million)
Table 32. Global Latisse (Bimatoprost) Revenue by Purity (2024-2029) & (US$ Million)
Table 33. Global Latisse (Bimatoprost) Revenue Share by Purity (2018-2023)
Table 34. Global Latisse (Bimatoprost) Revenue Share by Purity (2024-2029)
Table 35. Latisse (Bimatoprost) Price by Purity (2018-2023) & (US$/g)
Table 36. Global Latisse (Bimatoprost) Price Forecast by Purity (2024-2029) & (US$/g)
Table 37. Global Latisse (Bimatoprost) Sales by Application (2018-2023) & (g)
Table 38. Global Latisse (Bimatoprost) Sales by Application (2024-2029) & (g)
Table 39. Global Latisse (Bimatoprost) Sales Share by Application (2018-2023)
Table 40. Global Latisse (Bimatoprost) Sales Share by Application (2024-2029)
Table 41. Global Latisse (Bimatoprost) Revenue by Application (2018-2023) & (US$ Million)
Table 42. Global Latisse (Bimatoprost) Revenue by Application (2024-2029) & (US$ Million)
Table 43. Global Latisse (Bimatoprost) Revenue Share by Application (2018-2023)
Table 44. Global Latisse (Bimatoprost) Revenue Share by Application (2024-2029)
Table 45. Latisse (Bimatoprost) Price by Application (2018-2023) & (US$/g)
Table 46. Global Latisse (Bimatoprost) Price Forecast by Application (2024-2029) & (US$/g)
Table 47. US & Canada Latisse (Bimatoprost) Sales by Purity (2018-2023) & (g)
Table 48. US & Canada Latisse (Bimatoprost) Sales by Purity (2024-2029) & (g)
Table 49. US & Canada Latisse (Bimatoprost) Revenue by Purity (2018-2023) & (US$ Million)
Table 50. US & Canada Latisse (Bimatoprost) Revenue by Purity (2024-2029) & (US$ Million)
Table 51. US & Canada Latisse (Bimatoprost) Sales by Application (2018-2023) & (g)
Table 52. US & Canada Latisse (Bimatoprost) Sales by Application (2024-2029) & (g)
Table 53. US & Canada Latisse (Bimatoprost) Revenue by Application (2018-2023) & (US$ Million)
Table 54. US & Canada Latisse (Bimatoprost) Revenue by Application (2024-2029) & (US$ Million)
Table 55. US & Canada Latisse (Bimatoprost) Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 56. US & Canada Latisse (Bimatoprost) Revenue by Country (2018-2023) & (US$ Million)
Table 57. US & Canada Latisse (Bimatoprost) Revenue by Country (2024-2029) & (US$ Million)
Table 58. US & Canada Latisse (Bimatoprost) Sales by Country (2018-2023) & (g)
Table 59. US & Canada Latisse (Bimatoprost) Sales by Country (2024-2029) & (g)
Table 60. Europe Latisse (Bimatoprost) Sales by Purity (2018-2023) & (g)
Table 61. Europe Latisse (Bimatoprost) Sales by Purity (2024-2029) & (g)
Table 62. Europe Latisse (Bimatoprost) Revenue by Purity (2018-2023) & (US$ Million)
Table 63. Europe Latisse (Bimatoprost) Revenue by Purity (2024-2029) & (US$ Million)
Table 64. Europe Latisse (Bimatoprost) Sales by Application (2018-2023) & (g)
Table 65. Europe Latisse (Bimatoprost) Sales by Application (2024-2029) & (g)
Table 66. Europe Latisse (Bimatoprost) Revenue by Application (2018-2023) & (US$ Million)
Table 67. Europe Latisse (Bimatoprost) Revenue by Application (2024-2029) & (US$ Million)
Table 68. Europe Latisse (Bimatoprost) Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 69. Europe Latisse (Bimatoprost) Revenue by Country (2018-2023) & (US$ Million)
Table 70. Europe Latisse (Bimatoprost) Revenue by Country (2024-2029) & (US$ Million)
Table 71. Europe Latisse (Bimatoprost) Sales by Country (2018-2023) & (g)
Table 72. Europe Latisse (Bimatoprost) Sales by Country (2024-2029) & (g)
Table 73. China Latisse (Bimatoprost) Sales by Purity (2018-2023) & (g)
Table 74. China Latisse (Bimatoprost) Sales by Purity (2024-2029) & (g)
Table 75. China Latisse (Bimatoprost) Revenue by Purity (2018-2023) & (US$ Million)
Table 76. China Latisse (Bimatoprost) Revenue by Purity (2024-2029) & (US$ Million)
Table 77. China Latisse (Bimatoprost) Sales by Application (2018-2023) & (g)
Table 78. China Latisse (Bimatoprost) Sales by Application (2024-2029) & (g)
Table 79. China Latisse (Bimatoprost) Revenue by Application (2018-2023) & (US$ Million)
Table 80. China Latisse (Bimatoprost) Revenue by Application (2024-2029) & (US$ Million)
Table 81. Asia Latisse (Bimatoprost) Sales by Purity (2018-2023) & (g)
Table 82. Asia Latisse (Bimatoprost) Sales by Purity (2024-2029) & (g)
Table 83. Asia Latisse (Bimatoprost) Revenue by Purity (2018-2023) & (US$ Million)
Table 84. Asia Latisse (Bimatoprost) Revenue by Purity (2024-2029) & (US$ Million)
Table 85. Asia Latisse (Bimatoprost) Sales by Application (2018-2023) & (g)
Table 86. Asia Latisse (Bimatoprost) Sales by Application (2024-2029) & (g)
Table 87. Asia Latisse (Bimatoprost) Revenue by Application (2018-2023) & (US$ Million)
Table 88. Asia Latisse (Bimatoprost) Revenue by Application (2024-2029) & (US$ Million)
Table 89. Asia Latisse (Bimatoprost) Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 90. Asia Latisse (Bimatoprost) Revenue by Region (2018-2023) & (US$ Million)
Table 91. Asia Latisse (Bimatoprost) Revenue by Region (2024-2029) & (US$ Million)
Table 92. Asia Latisse (Bimatoprost) Sales by Region (2018-2023) & (g)
Table 93. Asia Latisse (Bimatoprost) Sales by Region (2024-2029) & (g)
Table 94. Middle East, Africa and Latin America Latisse (Bimatoprost) Sales by Purity (2018-2023) & (g)
Table 95. Middle East, Africa and Latin America Latisse (Bimatoprost) Sales by Purity (2024-2029) & (g)
Table 96. Middle East, Africa and Latin America Latisse (Bimatoprost) Revenue by Purity (2018-2023) & (US$ Million)
Table 97. Middle East, Africa and Latin America Latisse (Bimatoprost) Revenue by Purity (2024-2029) & (US$ Million)
Table 98. Middle East, Africa and Latin America Latisse (Bimatoprost) Sales by Application (2018-2023) & (g)
Table 99. Middle East, Africa and Latin America Latisse (Bimatoprost) Sales by Application (2024-2029) & (g)
Table 100. Middle East, Africa and Latin America Latisse (Bimatoprost) Revenue by Application (2018-2023) & (US$ Million)
Table 101. Middle East, Africa and Latin America Latisse (Bimatoprost) Revenue by Application (2024-2029) & (US$ Million)
Table 102. Middle East, Africa and Latin America Latisse (Bimatoprost) Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 103. Middle East, Africa and Latin America Latisse (Bimatoprost) Revenue by Country (2018-2023) & (US$ Million)
Table 104. Middle East, Africa and Latin America Latisse (Bimatoprost) Revenue by Country (2024-2029) & (US$ Million)
Table 105. Middle East, Africa and Latin America Latisse (Bimatoprost) Sales by Country (2018-2023) & (g)
Table 106. Middle East, Africa and Latin America Latisse (Bimatoprost) Sales by Country (2024-2029) & (g)
Table 107. Cayman Pharma Company Information
Table 108. Cayman Pharma Description and Major Businesses
Table 109. Cayman Pharma Latisse (Bimatoprost) Sales (g), Revenue (US$ Million), Price (US$/g) and Gross Margin (2018-2023)
Table 110. Cayman Pharma Latisse (Bimatoprost) Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Cayman Pharma Recent Developments
Table 112. Tecoland Corporation Company Information
Table 113. Tecoland Corporation Description and Major Businesses
Table 114. Tecoland Corporation Latisse (Bimatoprost) Sales (g), Revenue (US$ Million), Price (US$/g) and Gross Margin (2018-2023)
Table 115. Tecoland Corporation Latisse (Bimatoprost) Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Tecoland Corporation Recent Developments
Table 117. TCS Group Company Information
Table 118. TCS Group Description and Major Businesses
Table 119. TCS Group Latisse (Bimatoprost) Sales (g), Revenue (US$ Million), Price (US$/g) and Gross Margin (2018-2023)
Table 120. TCS Group Latisse (Bimatoprost) Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. TCS Group Recent Developments
Table 122. Changzhou BOHIV Company Information
Table 123. Changzhou BOHIV Description and Major Businesses
Table 124. Changzhou BOHIV Latisse (Bimatoprost) Sales (g), Revenue (US$ Million), Price (US$/g) and Gross Margin (2018-2023)
Table 125. Changzhou BOHIV Latisse (Bimatoprost) Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Changzhou BOHIV Recent Developments
Table 127. Zhejiang Ausun Company Information
Table 128. Zhejiang Ausun Description and Major Businesses
Table 129. Zhejiang Ausun Latisse (Bimatoprost) Sales (g), Revenue (US$ Million), Price (US$/g) and Gross Margin (2018-2023)
Table 130. Zhejiang Ausun Latisse (Bimatoprost) Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Zhejiang Ausun Recent Developments
Table 132. Ansion Pharma Company Information
Table 133. Ansion Pharma Description and Major Businesses
Table 134. Ansion Pharma Latisse (Bimatoprost) Sales (g), Revenue (US$ Million), Price (US$/g) and Gross Margin (2018-2023)
Table 135. Ansion Pharma Latisse (Bimatoprost) Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Ansion Pharma Recent Developments
Table 137. Lianmin Biochemical Company Information
Table 138. Lianmin Biochemical Description and Major Businesses
Table 139. Lianmin Biochemical Latisse (Bimatoprost) Sales (g), Revenue (US$ Million), Price (US$/g) and Gross Margin (2018-2023)
Table 140. Lianmin Biochemical Latisse (Bimatoprost) Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Lianmin Biochemical Recent Developments
Table 142. Chirogate International Company Information
Table 143. Chirogate International Description and Major Businesses
Table 144. Chirogate International Latisse (Bimatoprost) Sales (g), Revenue (US$ Million), Price (US$/g) and Gross Margin (2018-2023)
Table 145. Chirogate International Latisse (Bimatoprost) Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Chirogate International Recent Developments
Table 147. Everlight Chemical Company Information
Table 148. Everlight Chemical Description and Major Businesses
Table 149. Everlight Chemical Latisse (Bimatoprost) Sales (g), Revenue (US$ Million), Price (US$/g) and Gross Margin (2018-2023)
Table 150. Everlight Chemical Latisse (Bimatoprost) Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Everlight Chemical Recent Developments
Table 152. GENTEC Company Information
Table 153. GENTEC Description and Major Businesses
Table 154. GENTEC Latisse (Bimatoprost) Sales (g), Revenue (US$ Million), Price (US$/g) and Gross Margin (2018-2023)
Table 155. GENTEC Latisse (Bimatoprost) Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. GENTEC Recent Developments
Table 157. Key Raw Materials Lists
Table 158. Raw Materials Key Suppliers Lists
Table 159. Latisse (Bimatoprost) Distributors List
Table 160. Latisse (Bimatoprost) Customers List
Table 161. Latisse (Bimatoprost) Market Trends
Table 162. Latisse (Bimatoprost) Market Drivers
Table 163. Latisse (Bimatoprost) Market Challenges
Table 164. Latisse (Bimatoprost) Market Restraints
Table 165. Research Programs/Design for This Report
Table 166. Key Data Information from Secondary Sources
Table 167. Key Data Information from Primary Sources
List of Figures
Figure 1. Latisse (Bimatoprost) Product Picture
Figure 2. Global Latisse (Bimatoprost) Market Size Growth Rate by Purity, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Latisse (Bimatoprost) Market Share by Purity in 2022 & 2029
Figure 4. Below 99.5% Product Picture
Figure 5. Other Product Picture
Figure 6. Global Latisse (Bimatoprost) Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global Latisse (Bimatoprost) Market Share by Application in 2022 & 2029
Figure 8. Patented Product
Figure 9. General Products
Figure 10. Latisse (Bimatoprost) Report Years Considered
Figure 11. Global Latisse (Bimatoprost) Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global Latisse (Bimatoprost) Revenue 2018-2029 (US$ Million)
Figure 13. Global Latisse (Bimatoprost) Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 14. Global Latisse (Bimatoprost) Revenue Market Share by Region (2018-2029)
Figure 15. Global Latisse (Bimatoprost) Sales 2018-2029 ((g)
Figure 16. Global Latisse (Bimatoprost) Sales Market Share by Region (2018-2029)
Figure 17. US & Canada Latisse (Bimatoprost) Sales YoY (2018-2029) & (g)
Figure 18. US & Canada Latisse (Bimatoprost) Revenue YoY (2018-2029) & (US$ Million)
Figure 19. Europe Latisse (Bimatoprost) Sales YoY (2018-2029) & (g)
Figure 20. Europe Latisse (Bimatoprost) Revenue YoY (2018-2029) & (US$ Million)
Figure 21. China Latisse (Bimatoprost) Sales YoY (2018-2029) & (g)
Figure 22. China Latisse (Bimatoprost) Revenue YoY (2018-2029) & (US$ Million)
Figure 23. Asia (excluding China) Latisse (Bimatoprost) Sales YoY (2018-2029) & (g)
Figure 24. Asia (excluding China) Latisse (Bimatoprost) Revenue YoY (2018-2029) & (US$ Million)
Figure 25. Middle East, Africa and Latin America Latisse (Bimatoprost) Sales YoY (2018-2029) & (g)
Figure 26. Middle East, Africa and Latin America Latisse (Bimatoprost) Revenue YoY (2018-2029) & (US$ Million)
Figure 27. The Latisse (Bimatoprost) Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 28. The Top 5 and 10 Largest Manufacturers of Latisse (Bimatoprost) in the World: Market Share by Latisse (Bimatoprost) Revenue in 2022
Figure 29. Global Latisse (Bimatoprost) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 30. Global Latisse (Bimatoprost) Sales Market Share by Purity (2018-2029)
Figure 31. Global Latisse (Bimatoprost) Revenue Market Share by Purity (2018-2029)
Figure 32. Global Latisse (Bimatoprost) Sales Market Share by Application (2018-2029)
Figure 33. Global Latisse (Bimatoprost) Revenue Market Share by Application (2018-2029)
Figure 34. US & Canada Latisse (Bimatoprost) Sales Market Share by Purity (2018-2029)
Figure 35. US & Canada Latisse (Bimatoprost) Revenue Market Share by Purity (2018-2029)
Figure 36. US & Canada Latisse (Bimatoprost) Sales Market Share by Application (2018-2029)
Figure 37. US & Canada Latisse (Bimatoprost) Revenue Market Share by Application (2018-2029)
Figure 38. US & Canada Latisse (Bimatoprost) Revenue Share by Country (2018-2029)
Figure 39. US & Canada Latisse (Bimatoprost) Sales Share by Country (2018-2029)
Figure 40. U.S. Latisse (Bimatoprost) Revenue (2018-2029) & (US$ Million)
Figure 41. Canada Latisse (Bimatoprost) Revenue (2018-2029) & (US$ Million)
Figure 42. Europe Latisse (Bimatoprost) Sales Market Share by Purity (2018-2029)
Figure 43. Europe Latisse (Bimatoprost) Revenue Market Share by Purity (2018-2029)
Figure 44. Europe Latisse (Bimatoprost) Sales Market Share by Application (2018-2029)
Figure 45. Europe Latisse (Bimatoprost) Revenue Market Share by Application (2018-2029)
Figure 46. Europe Latisse (Bimatoprost) Revenue Share by Country (2018-2029)
Figure 47. Europe Latisse (Bimatoprost) Sales Share by Country (2018-2029)
Figure 48. Germany Latisse (Bimatoprost) Revenue (2018-2029) & (US$ Million)
Figure 49. France Latisse (Bimatoprost) Revenue (2018-2029) & (US$ Million)
Figure 50. U.K. Latisse (Bimatoprost) Revenue (2018-2029) & (US$ Million)
Figure 51. Italy Latisse (Bimatoprost) Revenue (2018-2029) & (US$ Million)
Figure 52. Russia Latisse (
|
Global Latisse (Bimatoprost) Market Research Report 2023
Bimatoprost (CAS 155206-00-1), also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic soluti... |
|
Global Latisse (Bimatoprost) Market Growth 2023-2029
Bimatoprost (CAS 155206-00-1), also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic soluti... |
|
Global Latisse (Bimatoprost) (CAS 155206-00-1) Market Insights: Impact of COVID-19 and Future Expectations to 2028
The Latisse (Bimatoprost) (CAS 155206-00-1) market revenue was 253.46 Million USD in 2022, and will reach 205.12 Million USD in 2028, with a CAGR of -3.47% during 2022-2028. This report elaborates the market size, market characteristic... |
|
Global Latisse Bimatoprost (CAS 155206 00 1) Market Research Report 2023 (Status and Outlook)
Report Overview Bimatoprost is a medication used to treat high pressure inside the eye including glaucoma.Specifically it is used for open angle glaucoma when other agents are not sufficient.It may also be used to increase the size of th... |
|
Global Latisse (Bimatoprost) ( CAS 155206-00-1) Market Insights: Impact of COVID-19 and Future Expectations to 2028
The Latisse (Bimatoprost) ( CAS 155206-00-1) market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028. This report elaborates the market size, market characteristics, and mar... |
|
Global Latisse (Bimatoprost) (CAS 155206-00-1) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Market Overview of Global Latisse (Bimatoprost) (CAS 155206-00-1) market: According to our latest research, the global Latisse (Bimatoprost) (CAS 155206-00-1) market looks promising in the next 5 years. As of 2022, the global Latisse (Bimatopro... |
|
Global Latisse (Bimatoprost) Market Outlook 2022
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segme... |
|
Global Latisse (Bimatoprost) Market Insights and Forecast to 2028
Latisse (Bimatoprost) market is segmented by Purity and by Application. Players, stakeholders, and other participants in the global Latisse (Bimatoprost) market will be able to gain the upper hand as they use the report as a powerful resource. The se... |
|
Global Latisse (Bimatoprost) ( CAS 155206-00-1) Market Research Report 2021 - Impact of COVID-19 on the Market
The Latisse (Bimatoprost) ( CAS 155206-00-1) market revenue was xx Million USD in 2016, grew to xx Million USD in 2021, and will reach xx Million USD in 2026, with a CAGR of xx during 2021-2026. Considering the influence of COV... |
|
Global Latisse (Bimatoprost) ( CAS 155206-00-1) Market Insights, Forecast to 2028
Latisse (Bimatoprost) ( CAS 155206-00-1) market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Latisse (Bimatoprost) ( CAS 155206-00-1) market will be able to gain the upper hand as they use the r... |
